VetReach: Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders

VA Office of Research and Development (U.S. Fed)
Overall Status
Recruiting ID
VA Ann Arbor Healthcare System (U.S. Fed)

Study Details

Study Description

Brief Summary

This project will pilot-test and obtain stakeholder input on a telehealth-delivered substance use disorder (SUD) care model (with initial engagement and ongoing MI-CBT treatment) with the goal of increasing treatment utilization and improving outcomes for rural and non-rural Veterans with SUDs.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: VetReach

Study Design

Study Type:
Anticipated Enrollment :
100 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
Using Telehealth to Expand Treatment Access for Veterans With Opioid Use Disorder (CDA 18-008)
Actual Study Start Date :
May 19, 2022
Anticipated Primary Completion Date :
Sep 30, 2026
Anticipated Study Completion Date :
Sep 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: MI-CBT Teletx

The intervention consists of an initial 30-60 min phone-delivered Engagement session that focuses on MI to help participants build self-efficacy and motivation to engage and to empower them to plan change and use Elicit-Provide-Elicit (EPE) to address treatment barriers (e.g., stigma, appeal, accessibility). Participants will then complete up to 8 ~50 minute Teletx weekly sessions via videoconference (or phone if needed). The intervention is highly patient-centered, by meeting and assessing patients where they are including in their unique context (i.e. rural community), helping them identify reasons and motivations for change, and centered around their goals (e.g. substance use reduction or abstinence).

Behavioral: VetReach
Telehealth-delivered MI-CBT substance use disorder care model

Outcome Measures

Primary Outcome Measures

  1. Feasibility of the intervention (engagement) [8 weeks]

    Percent (%) of participants engaging in the intervention (at least 3 completed sessions)

  2. Acceptability of the telehealth intervention [2 months]

    Study-specific acceptability rating completed by participants (% with a positive rating, higher % is better)

Other Outcome Measures

  1. Change in substance consumption [baseline, 8 weeks post-baseline]

    Substance use/consumption will be assessed using the 30-day Timeline Follow-Back (TLFB). The TLFB will capture information on the frequency and quantity of substance use, with total consumption calculated.

  2. Change in frequency of substance use as reported on the Timeline Follow-Back (TLFB) [baseline, 8 weeks post-baseline]

    Based on frequency and quantity, higher scores indicate worse outcome.

Eligibility Criteria


Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Veteran patients at the Ann Arbor VA Healthcare System

  • Diagnostic and Statistical Manual of Mental Disorders (DSM-5) SUD diagnosis and/or substance use on average of 2 days a week over the past month

  • Telephone access

  • Able to provide informed consent

Exclusion Criteria:
  • Receiving SUD psychotherapy

  • Inability to speak or understand English

  • Substantial mental health instability or conditions that preclude informed consent (e.g., acute psychosis, cognitive deficits) or understanding of assessment or program content

  • Prior alcohol withdrawal seizures or delirium tremens

Contacts and Locations


Site City State Country Postal Code
1 VA Ann Arbor Healthcare System, Ann Arbor, MI Ann Arbor Michigan United States 48105

Sponsors and Collaborators

  • VA Office of Research and Development
  • VA Ann Arbor Healthcare System


  • Principal Investigator: Lewei Lin, MD, VA Ann Arbor Healthcare System, Ann Arbor, MI

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
VA Office of Research and Development Identifier:
Other Study ID Numbers:
  • CDX 22-007
  • PROJ-03672
First Posted:
Apr 27, 2022
Last Update Posted:
May 27, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Product Manufactured in and Exported from the U.S.:
Keywords provided by VA Office of Research and Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2022